303094-67-9
303094-67-9
Chemical Structure
ZINC69391
- CAS No.: 303094-67-9
- Formula:C14H14F3N5
- Molecular Weight:309.29
IUPAC Name: 1-(4,6-dimethylpyrimidin-2-yl)-3-(2-(trifluoromethyl)phenyl)guanidine
InChIKey: BEZGMANANMSUSQ-UHFFFAOYSA-N
SMILES: N=C(NC1=CC=CC=C1C(F)(F)F)NC2=NC(C)=CC(C)=N2
Biological Activity: ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ZINC69391 | 99.12% | ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ZINC69391 (Standard) | ≥98% | ZINC69391 (Standard) is the analytical standard of ZINC69391 (HY-102078). This product is intended for research and analytical applications. ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cabrera M, et al. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017;8(58):98509‐98523. Published 2017 Oct 4. [Content Brief]
- [2]. Cardama GA, et al. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. Onco Targets Ther. 2014;7:2021‐2033. Published 2014 Oct 30. [Content Brief]
- [3]. Cardama GA, et al. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 2014;14(6):840‐851. [Content Brief]
